BioSpace News Archive

Deals

Verseon Acquires Edammo to Deepen Drug Discovery Approach

Verseon has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform. Financial terms were not disclosed.

October 14, 2022
·
4 min read
·
Mark Terry
Drug Development

Travere Anticipates 3-Month PDUFA Setback for IgA Nephropathy Treatment

The FDA is likely to push back the Prescription Drug User Fee Act target action date for Travere Therapeutics’ sparsentan by three months..

October 14, 2022
·
3 min read
·
Tristan Manalac
Research Roundup: Findings in Sickle Cell Disease, Alzheimer’s, Allergic Asthma and More

This week, new research is presented in treatments for sickle cell disease, Alzheimer’s, asthma, and type 1 diabetes. Here’s a look at that and more.

October 14, 2022
·
4 min read
·
Katherine Davis
Deals

Enliven and Imara Merge to Form Precision Oncology Company

Enliven Therapeutics and Imara will merge in an all-stock deal to form a precision oncology company. The new entity will operate under the name Enliven Therapeutics.

October 14, 2022
·
3 min read
·
Mark Terry
Business

Novartis, GSK and Sanofi Scale Back on Operations and Labor Forces Overseas - Updated

Novartis, GlaxoSmithKline and Sanofi have announced plans for significant cutbacks and changes in their labor force overseas for financial, operational and logistical reasons.

October 14, 2022
·
2 min read
·
Kaley Lefevre
Business

Mablink Breaks into ADC Space with $30M for Improved Linker Tech

France-based biotech Mablink secured $30 million (€31 million EUR) to develop next-generation antibody-drug conjugates for the treatment of cancer.

October 14, 2022
·
2 min read
·
Alex Keown
Drug Development

BridgeBio Bounces Back with Promising Canavan, MD Data

After suffering a blow to its multi-billion dollar liver cancer program, BridgeBio presented early but promising data in ultra-rare Canavan disease.

October 14, 2022
·
3 min read
·
Mark Terry
Drug Development

FDA Review: Phanes, Pfizer, GSK and More

The FDA has numerous activities and interactions with Phanes, Prestige Biopharma, Reata, Pfizer and more, providing clearance, approving clinical trials and other regulatory actions.

October 14, 2022
·
3 min read
·
Mark Terry
Business

Sanofi-Backed Matchpoint Launches with $100M for Precision Covalent Medicines - Updated

Matchpoint Therapeutics hit the ground running Friday with $100 million in investments and a focus on developing precision small molecule medicines.

October 14, 2022
·
2 min read
·
Alex Keown
Business

DaVita Inc. Schedules 3rd Quarter 2022 Investor Conference Call

DaVita Inc., announced that it will hold its quarterly conference call to discuss third quarter results on Friday, October 28, 2022, at 8:30 a.m. Eastern Time.

October 14, 2022
·
1 min read